Ditchcarbon
  • Contact
  1. Organizations
  2. Elanco US, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 8 months ago

Elanco US, Inc. Sustainability Profile

Company website

Elanco US, Inc., a leading global animal health company, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1954, Elanco has established itself as a key player in the animal health industry, focusing on innovative solutions for both livestock and companion animals. The company offers a diverse range of products and services, including vaccines, parasiticides, and nutritional supplements, all designed to enhance animal health and productivity. Elanco's commitment to research and development has led to significant advancements in animal care, positioning it as a trusted partner for veterinarians and farmers alike. With a strong market presence and a reputation for quality, Elanco continues to achieve notable milestones, reinforcing its status as a pioneer in the animal health sector.

DitchCarbon Score

How does Elanco US, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

57

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Elanco US, Inc.'s score of 57 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.

76%

Let us know if this data was useful to you

Elanco US, Inc.'s reported carbon emissions

Inherited from Elanco Animal Health Incorporated

Elanco US, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Elanco Animal Health Incorporated, which may influence its climate commitments and emissions reporting. While no specific reduction targets or achievements are listed for Elanco US, Inc., it is important to note that the broader corporate family, Elanco Animal Health Incorporated, may have established initiatives and targets related to carbon emissions reduction. However, details on these initiatives, including any Science-Based Targets Initiative (SBTi) commitments or other climate pledges, are not provided in the available data. As a subsidiary, Elanco US, Inc. may align its climate strategies with those of its parent company, which could include industry-standard practices for managing and reducing greenhouse gas emissions across various scopes. Without specific emissions data or reduction targets, the company's current climate commitments remain unclear.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20152018201920202021202220232024
Scope 1
274,550,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
418,271,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000

How Carbon Intensive is Elanco US, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Elanco US, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Elanco US, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Elanco US, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Elanco US, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Elanco US, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Elanco US, Inc.'s Emissions with Industry Peers

Zoetis

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Pharmgate LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Adm

US
•
Food products nec
Updated about 13 hours ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Boehringer Ingelheim International GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Huvepharma EOOD

BG
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy